US2020030369A1PendingUtilityA1

Modified Immune-Modulating Particles

62
Assignee: COUR PHARMACEUTICALS DEV COMPANY INCPriority: Nov 12, 2010Filed: Oct 16, 2019Published: Jan 30, 2020
Est. expiryNov 12, 2030(~4.3 yrs left)· nominal 20-yr term from priority
Inventors:Daniel R. GettsRachael TerryNicholas King
A61P 9/00A61P 37/02A61P 3/10A61P 9/04A61P 9/08A61P 37/06A61P 9/10A61P 37/08A61P 31/12A61P 29/00A61P 11/06A61P 25/00A61P 1/04A61P 17/06A61P 19/02A61P 11/02A61P 17/00A61K 9/0019A61K 47/50A61K 9/10A61K 9/48A61K 9/14Y10T428/2982A61K 31/765A61K 38/16A61K 31/19Y02A50/393Y02A50/30
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The current invention involves the surprising finding that when carboxylated particles, such as carboxylated poly-styrene, PLGA, or diamond particles are administered to subjects, inflammatory immune responses are ameliorated. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same carboxylated particles.

Claims

exact text as granted — not AI-modified
1 - 52 . (canceled) 
     
     
         53 . A pharmaceutical composition comprising poly (lactic-co-glycolic acid) (PLGA) particles modified to contain one or more carboxyl groups on the particle's surface, wherein the diameter of the particles is between 0.1 μm to 10 μm, and wherein the particles are free from therapeutically active ingredients. 
     
     
         54 . The pharmaceutical composition of claim  1 , wherein the diameter of the particles is about 0.5 μm. 
     
     
         55 . The pharmaceutical composition of claim  1 , wherein the diameter of the particles is between about 0.1 μm to about 1 μm. 
     
     
         56 . The pharmaceutical composition of claim  1 , wherein the diameter of the particles is between about 0.3 μm to about 5 μm. 
     
     
         57 . The pharmaceutical composition of claim  1 , wherein the diameter of the particles is between about 0.5 μm to about 3 μm. 
     
     
         58 . The pharmaceutical composition of claim  1 , wherein the particles are modified naked PLGA particles. 
     
     
         59 . The pharmaceutical composition of claim  1 , wherein the diameter of the particles is between about 0.5 μm to about 1 μm.

Join the waitlist — get patent alerts

Track US2020030369A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.